Nanobiotix S.A. (NBTX) Financial Analysis & Valuation | Quarter Chart
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, l... more
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the tr... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $1.69B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | FR | CEO | Laurent Levy |
| IPO Date | 2020-12-11 | CAGR | 24.62% |
| Employees | 97 | Website | www.nanobiotix.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NBTX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $695.08M | P/E | -56.29 | Forward P/E | -135.13 | PEG | — |
| P/S | 1.66 | P/B | -0.58 | P/CF | -1.45 | P/FCF | -1.45 |
| Sales | $26.11M | Sales 1Y | -45.22% | Sales 3Y | 272.97% | Sales 5Y | 230.87% |
| EPS | $-0.59 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -88.72% | EPS QoQ | 254.55% | Sales QoQ Avg | -174.89% | EPS QoQ Avg | 81.8% |
| Gross Margin | 100% | Operating Margin | -36.49% | Profit Margin | -80.83% | ROCE | -105.51% |
| ROA | -35% | ROE | 31% | Altman Z Score | 1.49 | Piotroski Score | 1 |
| Current Ratio | 1.09 | Quick Ratio | 1.09 | Cash Ratio | 0.92 | Op. CF Ratio | -0.28 |
| Debt/Equity | -1.13 | Debt/Assets | 1.41 | Lt Debt/Equity | -1.08 | Lt Debt/Cap. | 19.22 |
| Intrst Cov. | -1.04 | Inventory Turnover | — | Asset Turnover | 0.44 | Receivables Turnover | 3.86 |
| Enterprise Value | $695.08M | P/E Ratio | -56.29 |
| Forward P/E | -135.13 | PEG Ratio | — |
| P/S Ratio | 1.66 | P/B Ratio | -0.58 |
| P/CF Ratio | -1.45 | P/FCF Ratio | -1.45 |
| EPS | $-0.59 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -45.22% | Gross Margin | 100% |
| Operating Margin | -36.49% | Profit Margin | -80.83% |
| ROE | 31% | ROA | -35% |
| ROCE | -105.51% | Current Ratio | 1.09 |
| Quick Ratio | 1.09 | Cash Ratio | 0.92 |
| Debt/Equity | -1.13 | Interest Coverage | -1.04 |
| Altman Z Score | 1.49 | Piotroski Score | 1 |
Nanobiotix S.A. (NBTX) valuation & financials
Nanobiotix S.A. (NBTX) has a market capitalization of $1.69B and trades at a price-to-earnings ratio of -56.3. It operates in the Healthcare sector (Biotechnology).
Nanobiotix S.A.'s revenue grew -45.2% over the last year.
Nanobiotix S.A.'s next earnings report is scheduled for September 29, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.15. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)